sacituzumab tirumotecan + lorlatinib

Sacituzumab tirumotecan + lorlatinib is an investigational combination regimen being evaluated for the treatment of ALK fusion-positive non-small cell lung cancer (NSCLC). The regimen consists of sacituzumab tirumotecan (also known as SKB264 or MK-2870), a TROP2-directed antibody-drug conjugate (ADC), and lorlatinib, a third-generation tyrosine kinase inhibitor (TKI). Sacituzumab tirumotecan, developed by Kelun-Biotech and co-developed with Merck (MSD), utilizes a proprietary pyrimidine-thiol linker to deliver a novel topoisomerase I inhibitor payload to cells expressing TROP2. Lorlatinib, developed by Pfizer, is a potent inhibitor of ALK and ROS1 kinases designed to overcome resistance mutations. This combination is currently being studied in a Phase II clinical trial sponsored by the Guangdong Association of Clinical Trials, where patient selection is guided by peripheral blood circulating tumor DNA (ctDNA) analysis to identify ALK fusion-positive status in locally advanced or metastatic NSCLC.

Other names

SKB264 plus lorlatinibSKB-264 plus lorlatinibSKB 264 plus lorlatinibMK-2870 plus lorlatinibMK2870 plus lorlatinibMK 2870 plus lorlatinib